Shardul Amarchand Mangaldas Advised Eris Lifesciences Limited On The Acquisition Of Remaining Stake In Swiss Parenterals Limited
Shardul Amarchand Mangaldas advised Eris Lifesciences on acquiring remaining 30% stake in Swiss Parenterals for INR 423.30 crore.
Shardul Amarchand Mangaldas advised Eris Lifesciences Limited on the acquisition of remaining stake in Swiss Parenterals Limited
The leading law firm in India, Shardul Amarchand Mangaldas & Co. advised Eris Lifesciences Limited (ELL) on its proposed acquisition of the remaining 30% shareholding of Swiss Parenterals Limited (SPL) from Naishadh Shah, Director of SPL, for an aggregate consideration of INR 423.30 crores. The consideration will be discharged by ELL through the issuance of its equity shares to Naishadh Shah on a preferential basis.
Upon completion of the proposed acquisition, and subject to relevant stock exchange approvals, SPL will become a wholly owned subsidiary of ELL. The transaction marks a strategic step towards strengthening ELL’s control and operational integration over SPL.
The Shardul Amarchand Mangaldas team was led by Nivedita Tiwari (Partner) and Devesh Pandey (Partner), with support from Kuhuk Jain (Principal Associate), Anushka Ganguli (Associate) and Sourav Paul (Associate).
On tax-related aspects, the team included Gouri Puri (Partner), Rahul Yadav (Partner) and Nimish Malpani (Principal Associate).
Click to know more about Shardul Amarchand Mangaldas
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.